Gilead Sciences (GILD) EPS & PE Ratio History
Current and historical earning per share (EPS) and price to earnings (PE) ratio for Gilead Sciences (GILD) over the last 10 years. The current PE ratio for Gilead Sciences as of February 16, 2018 is 9.45.
|Medical||Medical - Biomedical and Genetics||$105.416B||$26.107B|
|Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.|